Skip to main content
Home

Cardiology Associations

This page includes news coverage of cardiology societies and associations. Follow these links for specific cardiology society news pages: American College of Cardiology (ACC), American Heart Association (AHA), American Society of Echocardiography (ASE),  American Society Nuclear Cardiology (ASNC), European Society of Cardiology (ESC), Heart Rhythm Society (HRS), Society for Cardiovascular Angiography Interventions (SCAI), Society of Cardiovascular Computed Tomography (SCCT), Transcatheter Cardiovascular Therapeutics (TCT), and Vascular Interventional Advances (VIVA). 

RSS icon

  • Cathie Biga, MSM, MACC, past president of the American College of Cardiology (ACC) and president/CEO of Cardiovascular Management of Illinois, spoke in a business session at ACC 2026 on the use of artificial intelligence analytics and said human interface is needed to make the data actionable.

    The key to AI cardiology analytics is human action

    While AI analytics has greatly increased the ease of access to vast amounts of cardiology data, action is still required to make it useful.
     

  • Michael Coords, MD, FSCCT, Medical Director of Cardiovascular Imaging, RadNet, a leader with the SCCT Health Policy and Practice Committee Regulatory Task Force, and incoming co-chair of the Health Policy and Practice Committee, says SCCT offers a unique blend of clinical education, business strategy, and networking to stay on top of CCTA's rapid proliferation.

    Radiologists: Take the deep dive into advanced cardiovascular CT at SCCT

    SCCT offers a unique blend of clinical education, business strategy, and networking to stay on top of CCTA's rapid proliferation.

  • Ronen Rubinshtein, MD, FACC, FESC, director, heart institute, Edith Wolfson Medical Center, in Holon, Israel, president elect for the Society of Cardiovascular Computed Tomography (SCCT), and chairman of the SCCT 2026 annual scientific meeting, explains plaque imaging, AI and structural heart disease are the spotlight at the meeting.

    Plaque imaging, AI and structural heart disease in the spotlight at SCCT 2026 meeting

    Coronary plaque imaging is an area many experts believe is driving a shift toward earlier detection and prevention of heart disease.

  • A figure from the new SCCT FFR-CT consensus document to help explain how the technology works to assess hemodynamic flow using CT imaging.

    CT-FFR standardized in new SCCT-SCAI consensus statement

    FFR-CT literature has reached a state of maturity where experts can comfortably start to provide guidelines to the wider community. 

  • Robert Hawkins, MD, MSC, assistant professor of cardiac surgery, University of Michigan, discusses the growing trends of surgical aortic valve replacement (SAVR) following prior transcatheter aortic valve replacement (TAVR) and how to best risk assess these patients using a new STS risk calculator.

    How to evaluate risk when TAVR patients require surgery later in life

    Robert Hawkins, MD, discussed an updated risk calculator—and the latest data on SAVR after TAVR—for a new video interview with Cardiovascular Business.

Edwards Evoque transcatheter tricuspid valve replacement TTVR

PVL after TTVR linked to much lower survival rate, fewer clinical benefits

TTVR has made a major impact on heart patients all over the world. Just like aortic and mitral valve replacement, however, paravalvular leak is a serious complication that can lead to much worse outcomes.

Video interview with Ronald Crystal, MD, chair, Department of Genetic Medicine at Weill Cornell Medicine, presented late-breaking findings on a first in-human, virus-delivered gene therapy trial to stop cardiomyopathy death in patients with Friedreich Ataxia (FA). #ACC #ACC26

New gene therapy may help protect the hearts of patients with Friedreich's ataxia

A majority of deaths from Friedreich's ataxia are associated with heart complications. A new treatment years in the making could provide some much-needed relief.

Prem Soman, MD, director of the Cardiac Amyloidosis Center and nuclear cardiology, and associate chief of cardiology at the University of Pittsburgh Medical Center Heart and Vascular Institute presented the late-breaking results from the long-term survival benefits and disease stabilization with the drug acoramidis in patients with transthyretin amyloid cardiomyopathy at ACC 2026.

Long-term cardiac amyloidosis survival benefits seen in extension acoramidis trial

Patient outcomes clearly show acoramidis reduces both all-cause mortality and cardiovascular hospitalizations, but the study also reinforced the importance of early diagnosis and prompt medical therapy. 
 

To unpack the large number of lat-breaking trials at the American College of Cardiology 2026 meeting, Cardiovascular Business spoke in the above video interview with Deepak L. Bhatt, MD, MPH, MBA, FACC, FAHA, FESC, MSCAI, director of the Mount Sinai Fuster Heart Hospital, who highlighted several studies he felt had the most scientific impact. This included a mix of drug, device and strategy trials pointing to advances in cardiology. #ACC #ACC26

Deepak Bhatt discusses some of the most impactful trials at ACC 2026

Bhatt describes a mix of drug, device and strategy trials pointing to advances in cardiovascular science.
 

Kathryn Berlacher, MD, MS, FACC, chair of the 2026 American College of Cardiology (ACC) 2026 Scientific Sessions, and clinical director of cardiology and a women's heart and cardio-obstetrics specialist at the University of Pittsburgh Medical Center, explains the major trend of artificial intelligence (AI) in cardiology, the use of coronary CT angiography (CCTA) for the first time at a medical meeting to scan attendees, and the rise in hands on, guideline, business and advocacy sessions.

Impactful innovations reshape learning and technology at ACC.26

ACC.26 Chair Kathryn Berlacher, MD, MS, explained some of the big trends at this year's meeting, including AI, CCTA, hands-on training and guideline sessions.

prescription drugs

Cost-related medication non-adherence declined after the Inflation Reduction Act

Lower Medicare drug costs translated into more patients taking their medications, leading to better outcomes.

robot reviewing heart data

AI-powered EHR alerts make a world of difference for cardiologists, heart patients

AI can help care teams identify heart patients who would benefit from TAVR or another life-changing valve intervention.

 Former American College of Cardiology president Hadley Wilson, MD, FACC, executive vice chair of Atrium Health's Sanger Heart and Vascular Institute, shared his thoughts on what he saw as the key studies in the above video interview with Cardiovascular Business. He covered numerous trials in more detail in the video. #ACC26 #ACC

Key clinical takeaways from ACC.26

Hadley Wilson, MD, a former American College of Cardiology president, spoke to Cardiovascular Business about several studies presented at ACC.26.

Pagination

    • First page « First
    • Previous page ‹ Previous
    • Page …4
    • Page 5
    • Page 6
    • Page 7
    • Current page 8
    • Page 9
    • Page 10
    • Page 11
    • Page 12 …
    • Next page Next ›
    • Last page Last »
Displaying 57 - 64 of 1542
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
 
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme